AstraZeneca Shares Slide After Wainua Misses Target in Heart Disease Trial

Trial miss hits AstraZeneca

AstraZeneca shares fell on Thursday after the company said Wainua missed its primary goal in a late-stage trial for transthyretin amyloid cardiomyopathy, or ATTR-CM, a rare heart disease caused by protein buildup in the heart.

The result is a setback for one of AstraZeneca’s efforts to expand Wainua beyond its current approved use and into a larger cardiovascular market.

Multiple outlets reported the stock fell about 9% to 10% after the announcement.

Wainua, also known as eplontersen, was developed with Ionis Pharmaceuticals.

What the trial showed

According to reporting on the company disclosure, the Phase 3 study did not show a statistically significant benefit on the composite cardiovascular outcome it was designed to measure.

The Times reported the study enrolled 1,432 patients across 20 countries and ran for 140 weeks. The company said adding Wainua did not provide a statistically significant benefit on the composite outcome of cardiovascular mortality and recurrent cardiovascular events.

AstraZeneca executive vice-president Sharon Barr said the result still advances scientific understanding of the disease, according to that report.

The failure comes at a sensitive moment for AstraZeneca, which has been trying to broaden beyond oncology and build more of its growth around other therapeutic areas.

Commercial and investor stakes

The miss weakens the case for Wainua as a broader cardiovascular product and may make commercialization in ATTR-CM harder.

Analysts quoted in coverage said the setback could hurt peak-sales expectations, although it does not necessarily change AstraZeneca’s longer-term sales targets.

The trial result also affects competitive positioning in ATTR-CM, where drugmakers are trying to establish or defend market share in a strategically important niche disease area.

What comes next

AstraZeneca said it plans to discuss the data with regulators and evaluate next steps.

That leaves open whether the company will continue to push for the ATTR-CM indication, pause development in the setting of the primary-endpoint miss, or look to subgroup or secondary-endpoint findings for a possible path forward.

For now, the setback does not affect Wainua’s existing approval for hereditary transthyretin amyloidosis-related polyneuropathy.

Investors will be watching for any updated guidance on Wainua’s commercial outlook and for a separate response from Ionis on the trial result.